Skip to main content
SpringerLink
Log in

Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Evans RM, Mangelsdorf DJ (2014) Nuclear receptors, RXR, and the big bang. Cell 157(1):255–266

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Lane MA, Bailey SJ (2005) Role of retinoid signalling in the adult brain. Prog Neurobiol 75(4):275–293

    Article  CAS  PubMed  Google Scholar 

  3. Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4(2):180–188

    Article  CAS  PubMed  Google Scholar 

  4. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503–1506

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M et al (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924

    Article  CAS  PubMed  Google Scholar 

  7. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE et al (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924

    Article  CAS  PubMed  Google Scholar 

  8. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J et al (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924

    Article  CAS  PubMed  Google Scholar 

  9. Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR et al (2013) Response to comments on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J (2014) Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. Neurobiol Aging 35(9):2091–2095

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Lefterov I, Schug J, Mounier A, Nam KN, Fitz NF, Koldamova R (2015) RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment. Neurobiol Dis 82:132–140

    Article  CAS  PubMed  Google Scholar 

  12. Balducci C, Paladini A, Micotti E, Tolomeo D, La Vitola P, Grigoli E et al (2015) The continuing failure of bexarotene in Alzheimer’s disease mice. J Alzheimers Dis 46(2):471–482

    Article  CAS  PubMed  Google Scholar 

  13. O’Hare E, Jeggo R, Kim EM, Barbour B, Walczak JS, Palmer P et al (2016) Lack of support for bexarotene as a treatment for Alzheimer’s disease. Neuropharmacology 100:124–130

    Article  PubMed  Google Scholar 

  14. McFarland K, Spalding TA, Hubbard D, Ma JN, Olsson R, Burstein ES (2013) Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson’s disease. ACS Chem Neurosci 4(11):1430–1438

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Riancho J, Ruiz-Soto M, Villagrá NT, Berciano J, Berciano MT, Lafarga M (2014) Compensatory motor neuron response to chromatolysis in the murine hSOD1 G93A model of amyotrophic lateral sclerosis. Front Cell Neurosci 8:346

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Neurology, University Hospital Marques de Valdecilla-IDIVAL, CIBERNED, Av Valdecilla, s/n, 39008, Santander, Spain

    Javier Riancho & Jose Berciano

  2. Anatomy and Cell Biology Department, University of Cantabria-IDIVAL, CIBERNED, Santander, Spain

    Maria T. Berciano & Miguel Lafarga

Authors
  1. Javier Riancho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria T. Berciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Berciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel Lafarga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Riancho.

Ethics declarations

Conflicts of interest

All authors declare that they have no conflicts of interest.

Ethical standards

This article does not directly contain clinical studies or patient data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riancho, J., Berciano, M.T., Berciano, J. et al. Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases. J Neurol 263, 177–178 (2016). https://doi.org/10.1007/s00415-015-8004-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-015-8004-0

Keywords

Search

Navigation